| アブストラクト | BACKGROUND: Antiangiogenic drugs are widely used in cancer therapy but are associated with various adverse events (AEs). This study systematically analyzed pharmacovigilance data from the FAERS to evaluate the safety profiles of five antiangiogenic drugs. RESEARCH DESIGN AND METHODS: FAERS data from Q1 2004 to Q3 2024 were retrospectively analyzed, and external validation was performed on the EudraVigilance database. To detect AE signals, disproportionality analysis was performed using four methods: the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), multi-item gamma Poisson shrinker (MGPS). Time-to-onset (TTO) analysis was conducted. Subgroup analyses were performed based on gender and clinical outcomes (death/non-death). RESULTS: Disproportionality analysis identified musculoskeletal and connective tissue disorders as the most significantly associated AE for fruquintinib (ROR: 2.45, 95% CI: 2.05-2.94). The most frequently reported AE was death (ROR: 3.11, 95% CI: 2.64-3.66). Subgroup analysis revealed that males had a higher number of AEs, with death being most frequently reported, while females predominantly reported increased blood pressure. TTO analysis showed that most AEs occurred within 30 days of treatment initiation for fruquintinib (60.62%), ramucirumab (54.48%), aflibercept (48.71%), and regorafenib (71.5%), while 90.11% of bevacizumab-related AEs occurred within 360 days. CONCLUSIONS: This study provides a comprehensive pharmacovigilance assessment of antiangiogenic drugs, highlighting distinct AE patterns and times. These findings may guide clinicians in optimizing AE monitoring and management strategies. |
|---|
| ジャーナル名 | Journal of gastrointestinal cancer |
|---|
| Pubmed追加日 | 2026/10/26 |
|---|
| 投稿者 | Wu, Bing-Xuan; Yu, Xin-Ning; Wu, Hua-Tao; Liu, Jing |
|---|
| 組織名 | The Breast Center, Cancer Hospital of Shantou University Medical College,;Shantou, 515041, China.;Department of General Surgery, First Affiliated Hospital of Shantou University;Medical College, Shantou, 515041, China.;Medical College, Shantou, 515041, China. htwu@stu.edu.cn.;Shantou, 515041, China. jliu12@stu.edu.cn.;Department of Physiology, Shantou University Medical College, Shantou, 515041,;China. jliu12@stu.edu.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42932028/ |
|---|
